An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

Preparing a selection of fascinating snakes for an exciting and educational school presentation ...

In infants and toddlers who had a stroke before birth or as a newborn (28 days or younger), a treatment that combined ...

The American Stroke Association, a division of the American Heart Association has expanded it's International Stroke Conference with multiple pre-conference symposiums in 2026. The meeting is in New ...

Pharmazz, Inc. today announced the presentation of positive interim results from its ongoing Phase IV clinical study of sovateltide (Tycamzzi®) in patients with acute cerebral ischemic stroke at the ...

For infants and toddlers who have had a stroke, a new treatment that restricted the use of their stronger arm and hand to encourage them to use their stroke-affected arm and hand, combined with ...

A new risk prediction tool was able to accurately identify stroke survivors with the highest risk for developing dementia within a ...

Bayer plans a late breaking presentation of Phase III trial results for its anticoagulant candidate asundexian in secondary ...

A straightforward review of Tim Hortons’ OREO donut and drive-thru experience, covering taste, texture, presentation, and ...

Lance Lee NEUROLOGY Director, Neuroscience Institute Adventist Health Glendale Lance Lee, MD, is a board-certified ...